Hamilton is known for a lot of medical innovation with Hamilton Health Sciences being in the top 10 research hospitals in Canada and McMaster University being one of the top 50 schools globally for medicine and health.
Fusion Pharmaceuticals goal is to create radiopharmaceuticals as precision medicines, and they have decided to lease with McMaster University which is a huge success of both!
Fusion Pharmaceuticals already have a relation to McMaster University because they are a spin off company of Centre for Probe Development and Commercialization. CPDC is hosted at the University and is founded by Dr. Valliant, a chemistry professor at the University.
The manufacturing facility aims to use this state-of-the-art building to support the company and their work with targeted alpha therapies (TATs).
“Having spun out of a radiopharmaceutical manufacturer, this is a core competency for Fusion, and we believe we are well-positioned to scale production in support of our pipeline of TATs, which now includes five clinical-stage programs” –Fusion Chief Executive Officer John Valliant, Ph.D.
The 27,000 square foot facility will be adjacent to the company’s other labs and research facilities on 270 Longwood Road South.
This significant life sciences investment aims to produce over 100,000 doses of TATs per year with the intent to help cancer.
This is a very exciting addition to Hamilton, and it is going to create so many opportunities for the company’s and institutions involved.